Keith Joung is a leading innovator in the field of gene editing. He is the Robert B. Colvin, M.D. Endowed Chair in Pathology and a Pathologist at Massachusetts General Hospital (MGH) and Professor of Pathology at Harvard Medical School. He is also a member of the Center for Cancer Research and the Center for Computational and Integrative Biology at MGH. Dr. Joung has been a pioneer in the development of important technologies for targeted gene editing and epigenetic editing of human cells. He has received numerous awards including the 2022 Samsung Ho-Am Prize in Medicine, an NIH Director’s Pioneer Award, an NIH Director’s Transformative Research Project R01 Award, the MGH Research Scholar Award (2011 and 2016), an NIH R35 MIRA (Maximizing Investigators Research Award), election into the American Association of University Pathologists, and designation as a “Highly Cited Researcher” for the past six consecutive years (2016-2021) by Thomson Reuters/Clarivate Analytics. He serves on the editorial boards of Cell Genomics, Genome Biology, Human Gene Therapy, and Trends in Biotechnology. He has co-founded multiple biotechnology companies including Beam Therapeutics (NASDAQ: BEAM), Chroma Medicine, Editas Medicine (NASDAQ: EDIT), ETx, Inc., Pairwise Plants, SeQure Dx, Inc., and Verve Therapeutics (NASDAQ: VERV). Dr. Joung holds a Ph.D. in genetics from Harvard University, an M.D. from Harvard Medical School and an A.B. magna cum laude in biochemical sciences from Harvard College.